Expert Opinion on Drug Safety. Taylor & Francis Ltd Gosselt, H R, van Lint, J A, Kosse, L J, Spuls, P I, Vonkeman, H E, Tas, S W, Hoentjen, F, Nurmohamed, M T, van den Bemt, B J F, van Doorn, M B A & Jessurun, N T 2023, ' Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases ', Expert opinion on drug safety . https://doi.org/10.1080/14740338.2023.2181340 Expert opinion on drug safety. Taylor & Francis Expert opinion on drug safety. Taylor and Francis Ltd.
Expert opinion on drug safety. Taylor and Francis Ltd. Westerink, H J, Kosse, L J, Jessurun, N T, Tubergen, A, Vonkeman, H E, Nurmohamed, M T, van den Bemt, B J F & de Vries, M 2022, ' Patients’ and health-care professionals’ perspectives on adverse drug reaction burden attributed to the use of biological DMARDs : a qualitative study ', Expert opinion on drug safety . https://doi.org/10.1080/14740338.2023.2134344 Expert opinion on drug safety. Informa Healthcare
Expert opinion on drug safety. Taylor and Francis Ltd. Roest, L H, Kosse, L J, van Lint, J A, Gosselt, H R, Scholl, J H G, van Puijenbroek, E, Vonkeman, H E, Tas, S W, Nurmohamed, M T, van den Bemt, B J F & Jessurun, N T 2022, ' Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases : a registry-based prospective multicenter cohort study ', Expert opinion on drug safety . https://doi.org/10.1080/14740338.2022.2115479 Expert Opinion on Drug Safety, 22(3), 203-211. Taylor & Francis Ltd Expert opinion on drug safety. Taylor & Francis Expert Opinion on Drug Safety, 22, 203-211 Expert Opinion on Drug Safety, 22, 3, pp. 203-211